Kura Oncology, Inc. (KURA) stock
KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.34−0.15 (-2.00%)
Close on Nov 18, 2026Market cap $652.97MP/E –Yield –
Kura Oncology total assets
Total assets on the balance sheet at the end of each period.
Kura Oncology's total assets was $566.50M at Sep 30, 2026. For fiscal 2025 it was $738.36M, down 2.9% from the year before. Over ten years it grew 23.8% a year on average. The highest annual figure on record is $760.16M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $738.36M | -2.9% |
| FY2024 | Dec 31, 2024 | $760.16M | +69.3% |
| FY2023 | Dec 31, 2023 | $448.94M | -1.6% |
| FY2022 | Dec 31, 2022 | $456.31M | -14.6% |
| FY2021 | Dec 31, 2021 | $534.05M | -17.5% |
| FY2020 | Dec 31, 2020 | $647.21M | +167.5% |
| FY2019 | Dec 31, 2019 | $241.97M | +32.7% |
| FY2018 | Dec 31, 2018 | $182.38M | +90.3% |
| FY2017 | Dec 31, 2017 | $95.85M | +37.3% |
| FY2016 | Dec 31, 2016 | $69.82M | -20.0% |
| FY2015 | Dec 31, 2015 | $87.26M | +6232.3% |
| FY2014 | Dec 31, 2014 | $1.38M | +15096.3% |
| FY2013 | Dec 31, 2013 | $9.07K | +9.2% |
| FY2012 | Dec 31, 2012 | $8.30K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $566.50M | -12.8% |
| Q2 FY2026 | Jun 30, 2026 | $587.79M | -13.9% |
| Q1 FY2026 | Mar 31, 2026 | $652.55M | -12.3% |
| Q4 FY2025 | Dec 31, 2025 | $738.36M | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $649.38M | +35.6% |
| Q2 FY2025 | Jun 30, 2025 | $682.43M | +32.5% |
| Q1 FY2025 | Mar 31, 2025 | $743.76M | +34.3% |
| Q4 FY2024 | Dec 31, 2024 | $760.16M | +69.3% |
| Q3 FY2024 | Sep 30, 2024 | $478.84M | +1.1% |
| Q2 FY2024 | Jun 30, 2024 | $515.12M | +4.1% |
| Q1 FY2024 | Mar 31, 2024 | $553.91M | +30.0% |
| Q4 FY2023 | Dec 31, 2023 | $448.94M | -1.6% |
| Q3 FY2023 | Sep 30, 2023 | $473.77M | +5.8% |
| Q2 FY2023 | Jun 30, 2023 | $494.74M | +4.9% |
| Q1 FY2023 | Mar 31, 2023 | $425.98M | -14.6% |
| Q4 FY2022 | Dec 31, 2022 | $456.31M | -14.6% |
| Q3 FY2022 | Sep 30, 2022 | $447.99M | -20.2% |
| Q2 FY2022 | Jun 30, 2022 | $471.43M | -19.4% |
| Q1 FY2022 | Mar 31, 2022 | $498.59M | -19.6% |
| Q4 FY2021 | Dec 31, 2021 | $534.05M | -17.5% |
| Q3 FY2021 | Sep 30, 2021 | $561.14M | +65.3% |
| Q2 FY2021 | Jun 30, 2021 | $584.89M | +65.7% |
| Q1 FY2021 | Mar 31, 2021 | $620.26M | +173.9% |
| Q4 FY2020 | Dec 31, 2020 | $647.21M | +167.5% |
| Q3 FY2020 | Sep 30, 2020 | $339.57M | +33.4% |
| Q2 FY2020 | Jun 30, 2020 | $353.00M | +32.9% |
| Q1 FY2020 | Mar 31, 2020 | $226.46M | +33.5% |
| Q4 FY2019 | Dec 31, 2019 | $241.97M | +32.7% |
| Q3 FY2019 | Sep 30, 2019 | $254.60M | +33.0% |
| Q2 FY2019 | Jun 30, 2019 | $265.69M | +105.0% |
| Q1 FY2019 | Mar 31, 2019 | $169.62M | +19.9% |
| Q4 FY2018 | Dec 31, 2018 | $182.38M | +90.3% |
| Q3 FY2018 | Sep 30, 2018 | $191.50M | +85.7% |
| Q2 FY2018 | Jun 30, 2018 | $129.63M | +132.1% |
| Q1 FY2018 | Mar 31, 2018 | $141.46M | +128.5% |
| Q4 FY2017 | Dec 31, 2017 | $95.85M | +37.3% |
| Q3 FY2017 | Sep 30, 2017 | $103.12M | – |
| Q2 FY2017 | Jun 30, 2017 | $55.85M | – |
| Q1 FY2017 | Mar 31, 2017 | $61.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $69.82M | – |
See a number that looks wrong?